• 1
    Hayden FG. Antiviral resistance in influenza viruses–implications for management and pandemic response. N Engl J Med 2006; 354:785788.
  • 2
    Pielak RM, Oxenoid K, Chou JJ. Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses. Structure 2011; 19:16551663.
  • 3
    Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:13631373.
  • 4
    Cheng PK, To AP, Leung TW, Leung PC, Lee CW, Lim WW. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). Emerg Infect Dis 2010; 16:155156.
  • 5
    Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328:12721275.
  • 6
    Hurt AC, Chotpitayasunondh T, Cox NJ et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12:240248.
  • 7
    Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16:13891391.
  • 8
    Duval X, van der Werf S, Blanchon T et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7:e1000362.
  • 9
    Nguyen JT, Hoopes JD, Le MH et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 2010; 5:e9332.
  • 10
    Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol 2011; 205:1018.
  • 11
    Varner MW, Rice MM, Anderson B et al. Influenza-like illness in hospitalized pregnant and postpartum women during the 2009–2010 H1N1 pandemic. Obstet Gynecol 2011; 118:593600.
  • 12
    Greer LG, Leff RD, Rogers VL et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 2011; 6(Suppl. 1):S89S93.
  • 13
    Greer LG, Leff RD, Rogers VL et al. Pharmacokinetics of oseltamivir in breast milk and maternal plasma. Am J Obstet Gynecol 2011; 204:524.
  • 14
    Meijer WJ, Bruinse HW, van den Broek MP, Kromdijk W, Wensing AM. Oseltamivir and its active metabolite cross the placenta at significant levels. Clin Infect Dis 2012; 54:16761677.
  • 15
    Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:124.
  • 16
    Louie JK, Gavali S, Acosta M et al. Children hospitalized with 2009 novel influenza A(H1N1) in California. Arch Pediatr Adolesc Med 2010; 164:10231031.
  • 17
    Farias JA, Fernandez A, Monteverde E et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med 2010; 36:10151022.
  • 18
    Pebody RG, Harris R, Kafatos G et al. Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. Emerg Infect Dis 2011; 17:990999.
  • 19
    Pollock SL, Sagan M, Oakley L, Fontaine J, Poffenroth L. Investigation of a pandemic H1N1 influenza outbreak in a remote First Nations community in northern Manitoba, 2009. Can J Public Health 2012; 103:9093.
  • 20
    Lee N, Choi KW, Chan PK et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510515.
  • 21
    Lee VJ, Yap J, Cook AR et al. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. N Engl J Med 2010; 362:21662174.
  • 22
    Toovey S, Rayner C, Prinssen E et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31:10971114.
  • 23
    Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther 2012; 17:143157.
  • 24
    You JH, Chan ES, Leung MY, Ip M, Lee NL. A cost-effectiveness analysis of “test” versus “treat” patients hospitalized with suspected influenza in Hong Kong. PLoS ONE 2012; 7:e33123.
  • 25
    Hsu J, Santesso N, Mustafa R et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512524.
  • 26
    Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51:11671175.
  • 27
    Lee N, Chan PK, Lui GC et al. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011; 203:17391747.
  • 28
    Viasus D, Pano-Pardo JR, Pachon J et al. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. Chest 2011; 140:10251032.
  • 29
    Bautista E, Chotpitayasunondh T, Gao Z et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:17081719.
  • 30
    Lee N, Chan PK, Wong CK et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011; 16:237247.
  • 31
    Storms AD, Gubareva LV, Su S et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010–11. Emerg Infect Dis 2012; 18:308311.